{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:15:18Z","timestamp":1776057318960,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,1,2]],"date-time":"2016-01-02T00:00:00Z","timestamp":1451692800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s10620-015-4022-0","type":"journal-article","created":{"date-parts":[[2016,1,2]],"date-time":"2016-01-02T05:32:28Z","timestamp":1451712748000},"page":"1757-1762","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Refractory Autoimmune Hepatitis: Beyond Standard Therapy"],"prefix":"10.1007","volume":"61","author":[{"given":"Jonah N.","family":"Rubin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen S.","family":"Te","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,1,2]]},"reference":[{"key":"4022_CR1","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/apt.12042","volume":"36","author":"V Selvarajah","year":"2012","unstructured":"Selvarajah V, Montano-Loza AJ, Czaja AJ. Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. Aliment Pharmacol Ther. 2012;36:691\u2013707.","journal-title":"Aliment Pharmacol Ther"},{"key":"4022_CR2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1586\/egh.13.21","volume":"7","author":"AJ Czaja","year":"2013","unstructured":"Czaja AJ. Autoimmune hepatitis in diverse ethnic populations and geographical regions. Expert Rev Gastroenterol Hepatol. 2013;7:365\u2013385.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"4022_CR3","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/hep.23584","volume":"51","author":"MP Manns","year":"2010","unstructured":"Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193\u20132213.","journal-title":"Hepatology"},{"key":"4022_CR4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1055\/s-0029-1233534","volume":"29","author":"CP Strassburg","year":"2009","unstructured":"Strassburg CP, Manns MP. Treatment of autoimmune hepatitis. Semin Liver Dis. 2009;29:273\u2013285.","journal-title":"Semin Liver Dis"},{"key":"4022_CR5","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jhep.2010.01.037","volume":"53","author":"MM Lamers","year":"2010","unstructured":"Lamers MM, van Oijen MG, Pronk M, Drenth JP. Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. J Hepatol. 2010;53:191\u2013198.","journal-title":"J Hepatol"},{"key":"4022_CR6","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2010.06.046","volume":"139","author":"MP Manns","year":"2010","unstructured":"Manns MP, Woynarowski M, Kreisel W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 2010;139:1198\u20131206.","journal-title":"Gastroenterology"},{"key":"4022_CR7","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jhep.2010.12.032","volume":"55","author":"K Zachou","year":"2011","unstructured":"Zachou K, Gatselis N, Papadamou G, Rigopoulou EI, Dalekos GN. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients. J Hepatol. 2011;55:636\u2013646.","journal-title":"J Hepatol"},{"key":"4022_CR8","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1155\/2010\/891252","volume":"24","author":"K Sharzehi","year":"2010","unstructured":"Sharzehi K, Huang MA, Schreibman IR, Brown KA. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy. Can J Gastroenterol. 2010;24:588\u2013592.","journal-title":"Can J Gastroenterol"},{"key":"4022_CR9","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1111\/j.1572-0241.2008.02180.x","volume":"103","author":"EM Hennes","year":"2008","unstructured":"Hennes EM, Oo YH, Schramm C, et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol. 2008;103:3063\u20133070.","journal-title":"Am J Gastroenterol"},{"key":"4022_CR10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jceh.2014.05.003","volume":"4","author":"D Jothimani","year":"2014","unstructured":"Jothimani D, Cramp ME, Cross TJ. Role of mycophenolate mofetil for the treatment of autoimmune hepatitis-an observational study. J Clin Exp Hepatol. 2014;4:221\u2013225.","journal-title":"J Clin Exp Hepatol"},{"key":"4022_CR11","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1478-3231.2005.01107.x","volume":"25","author":"N Chatur","year":"2005","unstructured":"Chatur N, Ramji A, Bain VG, et al. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int. 2005;25:723\u2013727.","journal-title":"Liver Int"},{"key":"4022_CR12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2036.2011.04727.x","volume":"34","author":"AM Baven-Pronk","year":"2011","unstructured":"Baven-Pronk AM, Coenraad MJ, van Buuren HR, et al. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. Aliment Pharmacol Ther. 2011;34:335\u2013343.","journal-title":"Aliment Pharmacol Ther"},{"key":"4022_CR13","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1023\/A:1010683817344","volume":"46","author":"R Malekzadeh","year":"2001","unstructured":"Malekzadeh R, Nasseri-Moghaddam S, Kaviani MJ, Taheri H, Kamalian N, Sotoudeh M. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci. 2001;46:1321\u20131327.","journal-title":"Dig Dis Sci"},{"key":"4022_CR14","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1572-0241.1999.00807.x","volume":"94","author":"NF Fernandes","year":"1999","unstructured":"Fernandes NF, Redeker AG, Vierling JM, Villamil FG, Fong TL. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol. 1999;94:241\u2013248.","journal-title":"Am J Gastroenterol"},{"key":"4022_CR15","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S0168-8278(05)80615-4","volume":"21","author":"KE Sherman","year":"1994","unstructured":"Sherman KE, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. J Hepatol. 1994;21:1040\u20131047.","journal-title":"J Hepatol"},{"key":"4022_CR16","first-page":"771","volume":"90","author":"DH Thiel Van","year":"1995","unstructured":"Van Thiel DH, Wright H, Carroll P, et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol. 1995;90:771\u2013776.","journal-title":"Am J Gastroenterol"},{"key":"4022_CR17","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/01.mcg.0000139050.67178.be","volume":"38","author":"BA Aqel","year":"2004","unstructured":"Aqel BA, Machicao V, Rosser B, Satyanarayana R, Harnois DM, Dickson RC. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol. 2004;38:805\u2013809.","journal-title":"J Clin Gastroenterol"},{"key":"4022_CR18","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.3748\/wjg.v13.i23.3232","volume":"13","author":"FS Larsen","year":"2007","unstructured":"Larsen FS, Vainer B, Eefsen M, Bjerring PN, Adel Hansen B. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol. 2007;13:3232\u20133236.","journal-title":"World J Gastroenterol"},{"key":"4022_CR19","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2036.2011.04749.x","volume":"34","author":"MM Tannous","year":"2011","unstructured":"Tannous MM, Cheng J, Muniyappa K, et al. Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre experience. Aliment Pharmacol Ther. 2011;34:405\u2013407.","journal-title":"Aliment Pharmacol Ther"},{"key":"4022_CR20","doi-asserted-by":"crossref","first-page":"7866","DOI":"10.1074\/jbc.M109.096222","volume":"285","author":"GA Soliman","year":"2010","unstructured":"Soliman GA, Acosta-Jaquez HA, Dunlop EA, et al. mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action. J Biol Chem. 2010;285:7866\u20137879.","journal-title":"J Biol Chem"},{"key":"4022_CR21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.critrevonc.2005.03.012","volume":"56","author":"AL Taylor","year":"2005","unstructured":"Taylor AL, Watson CJ, Bradley JA. Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol. 2005;56:23\u201346.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4022_CR22","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2249.2009.04051.x","volume":"159","author":"S Heidt","year":"2010","unstructured":"Heidt S, Roelen DL, Eijsink C, et al. Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help. Clin Exp Immunol. 2010;159:199\u2013207.","journal-title":"Clin Exp Immunol"},{"key":"4022_CR23","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.amjmed.2014.06.016","volume":"127","author":"H Chatrath","year":"2014","unstructured":"Chatrath H, Allen L, Boyer TD. Use of sirolimus in the treatment of refractory autoimmune hepatitis. Am J Med. 2014;127:1128\u20131131.","journal-title":"Am J Med"},{"key":"4022_CR24","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1097\/MPG.0b013e318291feaa","volume":"58","author":"J Kurowski","year":"2014","unstructured":"Kurowski J, Melin-Aldana H, Bass L, Alonso EM, Ekong UD. Sirolimus as rescue therapy in pediatric autoimmune hepatitis. J Pediatr Gastroenterol Nutr. 2014;58:e4\u2013e6.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"4022_CR25","first-page":"676","volume":"2","author":"P Boross","year":"2012","unstructured":"Boross P, Leusen JH. Mechanisms of action of CD20 antibodies. Am J Cancer Res. 2012;2:676\u2013690.","journal-title":"Am J Cancer Res"},{"key":"4022_CR26","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1155\/2013\/512624","volume":"27","author":"KW Burak","year":"2013","unstructured":"Burak KW, Swain MG, Santodomingo-Garzon T, et al. Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. Can J Gastroenterol. 2013;27:273\u2013280.","journal-title":"Can J Gastroenterol"},{"key":"4022_CR27","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ajg.2013.08.009","volume":"14","author":"SA Al-Busafi","year":"2013","unstructured":"Al-Busafi SA, Michel RP, Deschenes M. Rituximab for refractory autoimmune hepatitis: a case report. Arab J Gastroenterol. 2013;14:135\u2013138.","journal-title":"Arab J Gastroenterol"},{"key":"4022_CR28","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1159\/000322693","volume":"4","author":"E Barth","year":"2010","unstructured":"Barth E, Clawson J. A case of autoimmune hepatitis treated with rituximab. Case Rep Gastroenterol. 2010;4:502\u2013509.","journal-title":"Case Rep Gastroenterol"},{"key":"4022_CR29","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1478-3231.2006.01262.x","volume":"26","author":"ES Santos","year":"2006","unstructured":"Santos ES, Arosemena LR, Raez LE, O\u2019Brien C, Regev A. Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature. Liver Int. 2006;26:625\u2013629.","journal-title":"Liver Int"},{"key":"4022_CR30","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1097\/MCG.0b013e3180f60b7a","volume":"42","author":"JT Evans","year":"2008","unstructured":"Evans JT, Shepard MM, Oates JC, Self SE, Reuben A. Rituximab-responsive cryoglobulinemic glomerulonephritis in a patient with autoimmune hepatitis. J Clin Gastroenterol. 2008;42:862\u2013863.","journal-title":"J Clin Gastroenterol"},{"key":"4022_CR31","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1542\/peds.2011-1900","volume":"132","author":"D D\u2019Agostino","year":"2013","unstructured":"D\u2019Agostino D, Costaguta A, Alvarez F. Successful treatment of refractory autoimmune hepatitis with rituximab. Pediatrics. 2013;132:e526\u2013e530.","journal-title":"Pediatrics"},{"key":"4022_CR32","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1600-6143.2011.03833.x","volume":"12","author":"EG Kamburova","year":"2012","unstructured":"Kamburova EG, Koenen HJ, Boon L, Joosten I, Hilbrands LB. In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. Am J Transplant. 2012;12:341\u2013350.","journal-title":"Am J Transplant"},{"key":"4022_CR33","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/art.37871","volume":"65","author":"EG Kamburova","year":"2013","unstructured":"Kamburova EG, Koenen HJ, Joosten I, Hilbrands LB. CD19 is a useful B cell marker after treatment with rituximab: comment on the article by Jones et al. Arthritis Rheum. 2013;65:1130\u20131131.","journal-title":"Arthritis Rheum"},{"key":"4022_CR34","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1002\/art.34560","volume":"64","author":"JD Jones","year":"2012","unstructured":"Jones JD, Hamilton BJ, Rigby WF. Rituximab mediates loss of CD19 on B cells in the absence of cell death. Arthritis Rheum. 2012;64:3111\u20133118.","journal-title":"Arthritis Rheum"},{"key":"4022_CR35","doi-asserted-by":"crossref","first-page":"R131","DOI":"10.1186\/ar2798","volume":"11","author":"M Nakou","year":"2009","unstructured":"Nakou M, Katsikas G, Sidiropoulos P, et al. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther. 2009;11:R131.","journal-title":"Arthritis Res Ther"},{"key":"4022_CR36","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/cei.12481","volume":"180","author":"AP Trouvin","year":"2015","unstructured":"Trouvin AP, Jacquot S, Grigioni S, et al. Usefulness of monitoring of B cell depletion in rituximab-treated rheumatoid arthritis patients in order to predict clinical relapse: a prospective observational study. Clin Exp Immunol. 2015;180:11\u201318.","journal-title":"Clin Exp Immunol"},{"key":"4022_CR37","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.20430","volume":"50","author":"RJ Looney","year":"2004","unstructured":"Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab. Arthritis Rheum. 2004;50:2580\u20132589.","journal-title":"Arthritis Rheum"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-015-4022-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-015-4022-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-015-4022-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T19:49:58Z","timestamp":1559245798000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-015-4022-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,2]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["4022"],"URL":"https:\/\/doi.org\/10.1007\/s10620-015-4022-0","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,2]]}}}